These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 30742979)

  • 1. Nanomedicines in clinical practice: Are colloidal iron sucrose ready-to-use intravenous solutions interchangeable?
    Di Francesco T; Sublet E; Borchard G
    Eur J Pharm Sci; 2019 Apr; 131():69-74. PubMed ID: 30742979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory challenges of nanomedicines and their follow-on versions: A generic or similar approach?
    Mühlebach S
    Adv Drug Deliv Rev; 2018 Jun; 131():122-131. PubMed ID: 29966685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model.
    Toblli JE; Cao G; Oliveri L; Angerosa M
    Inflamm Allergy Drug Targets; 2012 Feb; 11(1):66-78. PubMed ID: 22309085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tackling the challenges of nanomedicines: are we ready?
    Hertig JB; Shah VP; Flühmann B; Mühlebach S; Stemer G; Surugue J; Moss R; Di Francesco T
    Am J Health Syst Pharm; 2021 Jun; 78(12):1047-1056. PubMed ID: 33599767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron sucrose: assessing the similarity between the originator drug and its intended copies.
    Di Francesco T; Philipp E; Borchard G
    Ann N Y Acad Sci; 2017 Nov; 1407(1):63-74. PubMed ID: 29168243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron polymaltose complexes: Could we spot physicochemical differences in medicines sharing the same active pharmaceutical ingredient?
    Di Francesco T; Delafontaine L; Philipp E; Lechat E; Borchard G
    Eur J Pharm Sci; 2020 Feb; 143():105180. PubMed ID: 31841697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory challenges and approaches to characterize nanomedicines and their follow-on similars.
    Mühlebach S; Borchard G; Yildiz S
    Nanomedicine (Lond); 2015 Mar; 10(4):659-74. PubMed ID: 25723097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceutical stability of colloidal saccharated iron oxide injection in normal saline.
    Hira D; Suzuki A; Kono Y; Shimokawa K; Matsuoka S; Hasumoto KY; Kawahara H; Onoue M; Fujita T; Okano T; Kakumoto M
    J Pharm Health Care Sci; 2018; 4():21. PubMed ID: 30062041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous Iron-Carbohydrate Nanoparticles and Their Similars. What Do We Choose?
    Mehedinti AM; Capusa C; Andreiana I; Mircescu G
    Maedica (Bucur); 2022 Jun; 17(2):436-448. PubMed ID: 36032600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medication practice in hospitals: are nanosimilars evaluated and substituted correctly?
    Knoeff J; Flühmann B; Mühlebach S
    Eur J Hosp Pharm; 2018 Mar; 25(2):79-84. PubMed ID: 29599970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitrosative stress and apoptosis in non-anemic healthy rats induced by intravenous iron sucrose similars versus iron sucrose originator.
    Toblli JE; Cao G; Angerosa M
    Biometals; 2015 Apr; 28(2):279-92. PubMed ID: 25609135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors influencing safety and efficacy of intravenous iron-carbohydrate nanomedicines: From production to clinical practice.
    Nikravesh N; Borchard G; Hofmann H; Philipp E; Flühmann B; Wick P
    Nanomedicine; 2020 Jun; 26():102178. PubMed ID: 32145382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originator.
    Stein J; Dignass A; Chow KU
    Curr Med Res Opin; 2012 Feb; 28(2):241-3. PubMed ID: 22181342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanomedicines: The magic bullets reaching their target?
    Flühmann B; Ntai I; Borchard G; Simoens S; Mühlebach S
    Eur J Pharm Sci; 2019 Feb; 128():73-80. PubMed ID: 30465818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to select a nanosimilar.
    Astier A; Barton Pai A; Bissig M; Crommelin DJA; Flühmann B; Hecq JD; Knoeff J; Lipp HP; Morell-Baladrón A; Mühlebach S
    Ann N Y Acad Sci; 2017 Nov; 1407(1):50-62. PubMed ID: 28715605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of total-dose iron sucrose infusions in patients with iron deficiency anemia.
    Wall GC; Pauly RA
    Am J Health Syst Pharm; 2008 Jan; 65(2):150-3. PubMed ID: 18192261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diluting ferric carboxymaltose in sodium chloride infusion solution (0.9% w/v) in polypropylene bottles and bags: effects on chemical stability.
    Philipp E; Braitsch M; Bichsel T; Mühlebach S
    Eur J Hosp Pharm; 2016 Jan; 23(1):22-27. PubMed ID: 26835007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmaceutical characterization and thermodynamic stability assessment of a colloidal iron drug product: iron sucrose.
    Shah RB; Yang Y; Khan MA; Raw A; Yu LX; Faustino PJ
    Int J Pharm; 2014 Apr; 464(1-2):46-52. PubMed ID: 24440404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Snapshots of Iron Speciation: Tracking the Fate of Iron Nanoparticle Drugs via a Liquid Chromatography-Inductively Coupled Plasma-Mass Spectrometric Approach.
    Neu HM; Alexishin SA; Brandis JEP; Williams AMC; Li W; Sun D; Zheng N; Jiang W; Zimrin A; Fink JC; Polli JE; Kane MA; Michel SLJ
    Mol Pharm; 2019 Mar; 16(3):1272-1281. PubMed ID: 30676753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous treatment of anaemia with an iron-sucrose preparation.
    SLACK HG; WILKINSON JF
    Lancet; 1949 Jan; 1(6540):11-4. PubMed ID: 18208026
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.